The monitors came alive again at what might have been midnight. No one had a working watch, and the yellow windows offered no clues—the sky beyond them remained a constant charcoal gray, as if the building had been wrapped in fog or had simply drifted free of the normal progression of hours. The six survivors had spread out across the trading floor, not by agreement but by the gravitational pull of mutual suspicion. Irma Becker had claimed a corner near the dead potted plants, her knitting needles still clicking. Dr. Hugo de Vries sat with his back against a concrete pillar, eyes closed but not sleeping. Dr. Lena Kappel had found a janitor's closet and was methodically inventorying its contents: industrial cleaning solvents, a mop bucket, three rolls of paper towels, a container of rat poison. Sofia Beltrame watched her from a distance, saying nothing. Agnieszka Kowalski had not moved from her cross-legged position on the floor. And Adrian van der Heijden had stationed himself at the largest remaining desk, as if proximity to a workstation might restore some of the authority he had wielded in his previous life.
The first screen flickered to life directly above van der Heijden's head. He flinched, then looked up with the expression of a man who had spent his career anticipating market movements and was unsettled to find himself the subject of someone else's algorithm.
The image was grainy, clearly captured by a surveillance camera, the timestamp in the corner reading 2022-03-14 14:37:22. It showed a boardroom. Van der Heijden recognized it immediately—the executive conference room at Meridian Capital, the one with the Baltic Sea view that had cost two hundred thousand euros to furnish. There he was, seated at the head of the table, younger by three years, gesturing with a pen at a projection screen covered in numbers.
"I don't have audio," de Vries said from his pillar. "But that's you."
"Yes." Van der Heijden's voice was flat. "That's me."
The footage cut to another angle, another day. Now he was on a telephone, the pen replaced by a stress ball that he squeezed rhythmically as he spoke. The screen split into quadrants: phone records scrolling on one side, financial statements on another, and on the bottom half, a slow pan across the facade of a medical clinic. The sign above the door read "Krimulda Pediatric Institute" in Latvian and English.
Lena Kappel stepped out of the janitor's closet, a bottle of bleach in her hand. "Krimulda," she said. "That's where the trial was conducted. The gene therapy trial."
"Shut up," van der Heijden said.
But the screen was not finished. New documents appeared, annotated with yellow highlighter that picked out key phrases. A bond prospectus for the Latvian National Health Service. A credit default swap agreement. A series of transactions that showed Meridian Capital had taken a massive short position against the very bonds that funded the clinic—and had done so six weeks before the trial results were announced, before anyone knew that the therapy had failed, before fourteen children died.
Kappel set down the bleach. "You knew. You knew the trial would fail, and you bet against the clinic's funding. You made money from their deaths."
"I didn't know anything. I made an investment decision based on available data. That's what I do."
"Available data." Kappel's voice had gone very quiet. "I was the one who provided that data. I signed off on the Phase II results. And you're telling me someone gave you my data before the official release?"
Van der Heijden didn't answer. The screen provided the answer for him: another document, this one showing a payment of eight hundred thousand euros from a Vanderbijl Industries subsidiary to a consulting firm that existed only on paper, a firm whose sole proprietor was Adrian van der Heijden's brother-in-law.
"You sold the results," Kappel said. "Someone inside Vanderbijl fed you the negative data before the trial was even complete, and you used it to destroy the clinic's funding. You didn't just profit from their deaths. You made their deaths inevitable. The clinic lost its funding. It couldn't afford proper follow-up care. Some of those children might have survived with monitoring and intervention, but there was no money for it."
Agnieszka Kowalski had opened her eyes. She was looking at van der Heijden with the kind of stillness that comes before an earthquake. Her lips moved, but no sound came out. She was reciting something—a name, perhaps. She had been reciting names for six years, ever since she had stood in a cemetery in eastern Latvia and watched her younger sister's coffin lowered into frozen ground. Elina had been patient number eleven in the Krimulda trial. She had been nine years old.
The screen went dark. Van der Heijden exhaled slowly. "All right. You've shown your evidence. What do you want me to say? That I'm sorry? I am sorry. I'm sorry those children died. I'm sorry my trades contributed to a funding shortfall. But I didn't design the therapy. I didn't falsify the data. I didn't administer the treatments. I moved money. That's what money does. It moves."
"And where did it move to?" Sofia Beltrame asked the question without inflection, as if she were reading from a manual.
"Excuse me?"
"You moved money away from the clinic. Where did it move to?"
Van der Heijden opened his mouth, then closed it. The screen flickered again, as if anticipating his hesitation. A new image appeared: the facade of a private clinic in the Helvetic Confederacy, all glass and steel and discreet signage. An invoice for gene-editing treatments. A waiting list composed entirely of names from the Forbes Global 2000. The therapy that had failed in Krimulda had not been abandoned. It had been refined, rebranded, and repriced for a different clientele.
"You took the technology and ran," Kappel said. "You let the poor children die so you could sell the improved version to billionaires."
Irma Becker's knitting needles had stopped. She was watching van der Heijden with an expression that was not quite judgment—she had seen too much to judge easily—but something closer to confirmation. As if she had always known men like this existed and was merely waiting to see how they performed when cornered.
"I need some air," van der Heijden said, and walked away from the group before anyone could object. The trading floor was large enough that he could disappear among the cubicles and abandoned terminals. No one followed him. They had their own screens to watch.
The monitors cycled through the rest of them with the impersonal efficiency of a corporate training video. Hugo de Vries was shown entering a private operating theater in a building that was not a hospital. The patient on the table was young, female, Eastern European. The procedure was not medically necessary. The footage was damning without being explicit—it showed enough to suggest, not enough to prove, which was somehow worse. De Vries watched himself with the detached fascination of a man who had performed thousands of surgeries and could no longer distinguish the ethical ones from the others.
Irma Becker's segment showed a series of storefronts across the Baltic republics: a midwifery clinic in Tartu, a women's health center in Liepaja, a nondescript apartment in the outskirts of Riga. The camera lingered on the faces of young women entering and leaving, their expressions shifting from hope to something hollowed out. Documents scrolled past: invoices for "consultation services," receipts for medical waste disposal, a shipping manifest for biological materials bound for a research institute in the North Sea Republic.
"Organ trafficking," de Vries said. "That's what you did. You ran a procurement network."
"I provided services to women in need," Irma said calmly. "What happened to the byproducts of those services was handled by others."
"Byproducts," Kappel repeated. "You're calling them byproducts."
"What would you call them, Dr. Kappel? You designed the therapies that created the demand for certain biological materials. I merely facilitated supply. We are all links in the same chain."
The screen moved on. Sofia Beltrame's segment was the shortest, which was somehow the most alarming. It showed a personnel file from the North Sea Republic's National Security Directorate, heavily redacted. Her photograph. Her code name: "Helga." A list of operations that had been blacked out entirely. A final notation: "Inactive, Classified, Do Not Contact." Beneath it, a single line that had escaped redaction: "Specialization: containment and disposal."
Van der Heijden had not returned. The others were too absorbed in their own exposures to notice. But Agnieszka had been counting the minutes. She rose silently from her position on the floor and walked in the direction van der Heijden had gone.
She found him in a glass-walled office at the far end of the trading floor. The door was closed. Through the glass, she could see him sitting at the desk, his head in his hands. He looked older than he had an hour ago, diminished, as if the video had drained something essential from him. He did not look up when she approached. She tried the door handle. It turned.
The office had once belonged to a senior trader. There was a nameplate on the desk, the letters too faded to read. A dead plant in the corner. A photograph of someone's children, the faces bleached by years of sunlight into anonymous silhouettes. Van der Heijden raised his head.
"I know who you are," he said. "You're the sister. Elina Kowalski's sister."
Agnieszka said nothing. She closed the door behind her.
"I looked up the trial records after the trade went through. I wanted to know what I had bet against. There was a photograph of the patients. Elina was the one with the braids, wasn't she? The one who was smiling even though she was sick."
"Don't." Agnieszka's voice was barely a whisper. "Don't say her name."
"I'm not making excuses. I'm not. But I need you to understand something. What I did—it was legal. Immoral, yes. But legal. I didn't break any laws. I exploited weaknesses in the system, but the system was designed to be exploited. That's what capital does. It finds the gaps and fills them. If I hadn't done it, someone else would have. That doesn't make it right, but it makes it inevitable. Your sister was killed by a machine, and I was just one of the gears."
Agnieszka looked at him for a long time. Then she reached into her pocket and withdrew a small object—a surgical scalpel, its blade wrapped in a strip of cloth. De Vries's scalpel, taken from his bag while everyone's attention was fixed on the monitors.
"That's the difference between us," she said. "You're a gear. I'm not."
She crossed the room before he could react. The blade went in below the sternum, angled upward, the way she had been taught by a man in Riga who had once worked for the Soviet Union's biological weapons program and who had taught her many things about the human body's vulnerabilities. Van der Heijden made a sound that was not quite a scream—more like the noise a machine makes when something vital breaks. His hands came up, not to fight but to grasp at her wrists, as if he were drowning and she were the only solid thing in reach.
"You wanted to know what the cards meant," Agnieszka said, her voice still calm, still quiet. "Mors tua, vita mea. Your death, my life. I've been carrying Elina's death for six years. Now it's your turn."
She withdrew the blade. Van der Heijden slumped forward onto the desk, his cheek pressing against the faded nameplate. His eyes were open but no longer seeing. The photograph of the anonymous children watched him with their bleached-out faces.
Agnieszka cleaned the scalpel on his jacket, then placed it on the desk beside his hand. Let them draw their own conclusions. Let them suspect de Vries, or Kappel, or Sofia Beltrame. Let them tear each other apart. She had not come here to survive. She had come here to close accounts.
She left the office and closed the door behind her. The glass walls showed everything: the body slumped over the desk, the scalpel gleaming under the fluorescent lights, the dead plant, the photograph. It was a diorama of consequence.
When she returned to the central trading floor, the others were still watching the monitors, which had gone dark again. De Vries was the first to notice her return.
"Where is van der Heijden?" he asked.
"He needed time alone."
Sofia Beltrame looked at Agnieszka with those eyes that had seen too much. "How much time?"
"I don't know. He didn't say."
There was a silence, the heavy kind. Then Dr. Kappel stood up. "I'll go check on him. We shouldn't be separating. It's not safe."
She walked toward the offices, her white coat catching the yellow light. The others watched her go. And then they heard her voice, flat and clinical, carrying across the empty trading floor:
"Someone bring me a sheet. He's dead."
When they gathered around the glass office, de Vries was the first to notice the scalpel. His hand went to his bag—to the pocket where he kept his personal instruments, a habit he had maintained since medical school. The pocket was empty.
"That's mine," he said. "That's my scalpel."
"Did you kill him?" Irma Becker asked.
"No. I didn't. Someone took it. Someone took it from my bag while we were watching the screens."
Everyone looked at everyone else. The accounting had begun.
Sofia Beltrame knelt beside the body and examined the wound with the practiced eye of someone who had seen many wounds. "Single entry. Angled upward. The killer knew where to strike. This wasn't rage. This was execution."
The monitors flickered again, one final time. The image that appeared was not of any of them. It was a live feed from a camera mounted somewhere in the building—a camera that showed the glass office, and the body, and the six figures standing around it. Someone was still watching. Someone was always watching. And in the corner of the screen, barely visible, a timestamp counted upward in fractions of a second, measuring the interval between one death and whatever was coming next.
No comments yet. Be the first to comment!